NASDAQ:INBX Inhibrx Biosciences (INBX) Stock Price, News & Analysis $93.11 +4.45 (+5.02%) Closing price 08/10/2026 04:00 PM EasternExtended Trading$94.00 +0.89 (+0.96%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inhibrx Biosciences Stock (NASDAQ:INBX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Inhibrx Biosciences alerts:Sign Up Key Stats Today's Range$88.05▼$94.0750-Day Range$79.25▼$103.8552-Week Range$20.57▼$155.29Volume336,636 shsAverage Volume218,378 shsMarket Capitalization$1.37 billionP/E RatioN/ADividend YieldN/APrice Target$150.00Consensus RatingHold Company Overview Inhibrx, Inc., headquartered in La Jolla, California, is a clinical-stage biotechnology company focused on the discovery and development of next-generation protein therapeutics. The company’s proprietary protein engineering platform enables the design and production of multispecific and multivalent biologics with tailored binding characteristics and favorable pharmacokinetic properties. By leveraging high-throughput screening and structure-based design, Inhibrx aims to create molecules that address challenging targets in oncology, regenerative medicine and other areas of unmet medical need. The company’s lead candidate, INBRX-109, is a tetravalent agonist of the receptor tyrosine kinase ROR2 designed to stimulate tissue repair and regeneration. INBRX-109 is being evaluated in early-stage clinical studies for indications such as chronic wounds and tissue damage. In addition to its ROR2 program, Inhibrx is advancing a pipeline of preclinical assets targeting pathways including Tie2 and neuropilin-2 (NRP2), each selected for their potential to modulate angiogenesis, immune responses or fibrotic processes. Founded in 2006, Inhibrx completed its initial public offering in 2016 and trades on the Nasdaq under the ticker INBX. The company collaborates with academic research centers and strategic industry partners to accelerate the translation of its engineered proteins from discovery through clinical development. Inhibrx’s leadership team brings together expertise in molecular biology, protein engineering, translational science and regulatory affairs to drive the advancement of its therapeutic candidates toward potential regulatory approval.AI Generated. May Contain Errors. Read More Inhibrx Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreINBX MarketRank™: Inhibrx Biosciences scored higher than 47% of companies evaluated by MarketBeat, and ranked 585th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingInhibrx Biosciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, 1 buy rating, 3 hold ratings, and 1 sell rating.Upside PotentialInhibrx Biosciences has a consensus price target of $150.00, representing about 61.1% upside from its current price of $93.11.Amount of Analyst CoverageInhibrx Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Inhibrx Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inhibrx Biosciences are expected to grow in the coming year, from ($10.15) to ($7.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibrx Biosciences is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibrx Biosciences is -11.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibrx Biosciences has a P/B Ratio of 169.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Inhibrx Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.63% of the float of Inhibrx Biosciences has been sold short.Short Interest Ratio / Days to CoverInhibrx Biosciences has a short interest ratio ("days to cover") of 9.04.Change versus previous monthShort interest in Inhibrx Biosciences has recently decreased by 0.38%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibrx Biosciences does not currently pay a dividend.Dividend GrowthInhibrx Biosciences does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.20 News SentimentInhibrx Biosciences has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Inhibrx Biosciences this week, compared to 2 articles on an average week.Search Interest6 people have searched for INBX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibrx Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders18.26% of the stock of Inhibrx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.46% of the stock of Inhibrx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Inhibrx Biosciences' insider trading history. Receive INBX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibrx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INBX Stock News HeadlinesInhibrx Biosciences (INBX) to Post Quarterly Earnings on WednesdayAugust 11 at 2:10 AM | americanbankingnews.comInhibrx Biosciences (NASDAQ:INBX) Downgraded by Wall Street Zen to SellAugust 1, 2026 | americanbankingnews.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 11 at 1:00 AM | Banyan Hill Publishing (Ad)Inhibrx Biosciences: The Whole Story Rides On INBRX-106July 25, 2026 | seekingalpha.comInhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 MillionJuly 16, 2026 | prnewswire.comInhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaJune 15, 2026 | prnewswire.comLifeSci Capital Reaffirms Their Buy Rating on Inhibrx Biosciences Inc (INBX)May 18, 2026 | theglobeandmail.comInhibrx Biosciences, Inc.: Inhibrx Reports First Quarter 2026 Financial ResultsMay 16, 2026 | finanznachrichten.deSee More Headlines INBX Stock Analysis - Frequently Asked Questions How have INBX shares performed this year? Inhibrx Biosciences' stock was trading at $79.00 on January 1st, 2026. Since then, INBX stock has increased by 17.9% and is now trading at $93.11. How were Inhibrx Biosciences' earnings last quarter? Inhibrx Biosciences, Inc. (NASDAQ:INBX) posted its quarterly earnings data on Thursday, May, 14th. The company reported ($2.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by $0.48. When did Inhibrx Biosciences IPO? Inhibrx Biosciences (INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager. Who are Inhibrx Biosciences' major shareholders? Top institutional shareholders of Inhibrx Biosciences include BlackRock Inc. (5.63%), Western Standard LLC (0.32%), Bank of New York Mellon Corp (0.18%) and Tema ETFs LLC (0.07%). Insiders that own company stock include Brendan P Eckelman, Mark Lappe, Global Investors Lp Viking, Jon Faiz Kayyem and Kristiina Md Vuori. View institutional ownership trends. How do I buy shares of Inhibrx Biosciences? Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibrx Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibrx Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), PayPal (PYPL), Zoom Communications (ZM), CrowdStrike (CRWD) and Moderna (MRNA). Company Calendar Last Earnings5/14/2026Today8/11/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 INBX's financial health is in the Yellow zone, according to TradeSmith. INBX has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INBX CIK2007919 Webwww.inhibrx.com Phone858-795-4220FaxN/AEmployees166Year Founded2017Price Target and Rating Average Price Target for Inhibrx Biosciences$150.00 High Price Target$150.00 Low Price Target$150.00 Potential Upside/Downside+61.1%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($8.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$140.05 million Net MarginsN/A Pretax Margin-10,014.08% Return on Equity-563.90% Return on Assets-72.32% Debt Debt-to-Equity Ratio12.58 Current Ratio6.46 Quick Ratio6.46 Sales & Book Value Annual Sales$1.30 million Price / Sales1,050.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.55 per share Price / Book169.29Miscellaneous Outstanding Shares14,670,000Free Float11,992,000Market Cap$1.37 billion OptionableOptionable Beta3.51 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:INBX) was last updated on 8/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
